IDSA : View All Letters to Congress on Emerging Infections

11/13/2012

Groups Urge Congress to Reauthorize Pandemic and All Hazards Preparedness Act (PAHPA) (PDF)

IDSA joined over 40 health organizations and companies to urge Congress to reauthorize PAHPA, wich includes key preparedness programs such as the Biomedical Advanced Research and Development Authority (BARDA), the BioShield Special Reserve Fund, Public Health Emergency Preparedness grants, and the Hospital Preparedness Program.

09/20/2012

IDSA Urges Timely Reauthorization of Pandemic and All Hazards Preparedness Act (PAHPA) (PDF)

IDSA sent a letter to key congressional negotiators urging them to quickly pass PAHPA reauthorization and to include a Senate provision creating a Strategic Investor to leverage venture capital for the development of new medical countermeasures.

02/15/2012

IDSA Comments on Preparedness Legislation (PDF)

IDSA sent a letter to congressional sponsors of House and Senate legislation to reauthorize the Pandemic and All Hazards Preparedness Act (PAHPA) urging that key provisions from each chambers' proposal be included in the final legislation.

11/22/2011

IDSA Letter to Senate Sponsors of the Pandemic and All Hazards Preparedness (PAHPA) Reauthorization Act (PDF)

IDSA commends the PAHPA Reauthorization Act and encourages new provisions to incentivize antibiotic R&D, provide federal leadership to explore options for public private partnerships to focus on early antibiotic discovery research, and strengthen influenza preparedness and response.

08/19/2011

IDSA Letter to Senate Committee Regarding Reauthorization of the Pandemic All Hazards Preparedness Act (PAHPA) (PDF)

IDSA urges Congress to address antibiotic and related diagnostics development and antibiotic resistance coordination issues including through creation of an HHS-supported Strategic Investment Firm and an NIH-supported ID clinical specimen repository.

11/30/2010

IDSA Urges Appropriators to Fund Medical Countermeasures Review Recommendations (PDF)

IDSA sent a letter to all members of the House and Senate Appropriations Committees urging funding to implement fully the recommendations continued in the Administration's Medical Countermeasures Review report which was issued in August.

07/01/2010

IDSA Urges House to Preserve Unused Influenza Funding for Pandemic Preparedness (PDF)

IDSA and several public health groups wrote to House Appropriations Committee leaders and urged that unspent pandemic influenza preparedness funds be maintained for their intended purposes rather than being used as an offset for the Supplemental funding bill now under consideration.

05/01/2009

IDSA Joins Call for Emergency Influenza Funding (PDF)

IDSA supports emergency funding for pandemic influenza preparedness in light of the 2009 H1N1 influenza outbreak. Funds would be used for vaccine development, antivirals purchase, state and local efforts, global disease detection, purchases of personal protective equipment and antivirals for prophylaxis of healthcare workers, etc.

04/24/2009

IDSA Calls for Increased BARDA Funding (PDF)

IDSA supports Biomedical Advanced Research and Development Authority (BARDA) funding for bioemergency threats, including biological countermeasure and diagnostics R&D programs, in addition to BARDA's Pandemic and Emerging Disease Program.

09/09/2008

IDSA, Others Support Increased Funding for Pandemic Flu and Biodefense Preparedness (PDF)

IDSA and other members of the Working Group on Pandemic Influenza Preparedness sent a letter to Congressional leaders endorsing an Administration proposal to add $363 million for pandemic influenza activities at the Department of Health and Human Services and $542 million to the Biomedical Advanced Research and Development Authority (BARDA).

07/22/2008

IDSA Supports Creation of Public Health Emergency Medical Insurance Program (PDF)

IDSA, others, endorse the Public Health Emergency Response Act to provide medical coverage to uninsured persons and reimburse healthcare providers for services rendered during a public health emergency.

11/15/2007

IDSA Endorses 50% Tax Credit for Infectious Disease Product Research & Development (PDF)

New legislation, S. 2351, introduced by Senator Charles Schumer (D-NY), if enacted, will help to spur the development of new antibiotics, antiviral drugs, vaccines, diagnostics, and biological products to address MRSA, gram-negative bacterial infections, XDR-TB, and other dangerous drug-resistant and other infectious pathogens.

08/02/2006

IDSA Applauds Senate Leaders for their Efforts on the Pandemic and All Hazards Preparedness Act (PDF)

IDSA applauds Senate leaders for their efforts on S. 3678, the Pandemic and All Hazards Preparedness Act, but also endorses an independent expert commission and new federal Biomedical Advanced Research and Development Authority to study and stimulate much needed anti-infective drug and vaccine research and development.

11/08/2005

IDSA Opposes Stifling Small Business Admin. Action Affecting Biotech and Device Research & Development (PDF)

Building on its "Bad Bugs, No Drugs" effort, IDSA works with a coalitions to support a legislative fix.

07/05/2005

IDSA Endorses the Infectious Disease Research and Development Act of 2005 (PDF)

IDSA has endorsed H.R. 3154, The Infectious Diseases Research and Development Act of 2005, a bill sponsored by Congresswoman Barbara Cubin (D-WY). The bill, if enacted, will provide incentives for pharmaceutical and biotechnology companies to invest in research and development with respect to antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent a “qualified infectious disease product.”

04/11/2005

Prepare for Pandemic and Interpandemic Influenza (PDF)

IDSA urges congressional leaders to adopt IDSA remedies to strengthen U.S. preparedness and response efforts against influenza interpandemics and future pandemics.

View All Letters to Congress on Emerging Infections

Infectious Diseases Society of America